Skip to main content
    L

    Lantheus Holdings Inc (LNTH)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $101.72
    +0.13 (+0.13%)

    Market Cap: $6.64B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Lantheus Holdings Inc (LNTH) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Lantheus Holdings (LNTH) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Lantheus Holdings reported EPS of $1.43, above the $1.01 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    85%(34/40)
    Avg Surprise
    +60.01%
    Streak
    4 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.36
    Range$1.02 - $1.63
    11 analysts
    Revenue Consensus
    $382.29M
    Range$343.88M - $453.60M
    11 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$1.58
    Range$1.48 - $1.76
    3 analysts
    EPS Revisions
    3
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$1.43+10.2%
    60d ago$1.52+3.9%
    30d ago$1.52+3.9%
    7d ago$1.52+3.9%
    Current$1.58
    Revenue Consensus
    $403.95M
    Range$398.30M - $407.00M
    3 analysts

    Next Report

    LNTH has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 6.8% below the $1.46 reported for the quarter ended Dec 31, 2025.

    LNTH Earnings Call

    The latest LNTH earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, LNTH beat 34, missed 4 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $389.91M, up 1.5% from $384.01M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.43$1.01N/A+41.58%Beat+12.6%72 up, 1 downNov 5, 2026$389.91M
    Jun 30, 2026$1.32$1.11N/A+18.92%Beat-15.9%111 up, 1 downAug 6, 2026$388.18M
    Mar 31, 2026$1.46$1.23$1.08 - $1.34+18.70%Beat-4.6%120 up, 1 downMay 7, 2026$377.33M
    Dec 31, 2025$1.46$0.94$0.86 - $1.29+55.32%Beat-8.2%131 up, 0 downFeb 26, 2026$406.79M
    Sep 30, 2025$1.27$1.27$1.16 - $1.360.00%In line-25.3%131 up, 2 downNov 6, 2025$384.01M
    Jun 30, 2025$1.57$1.68$1.57 - $2.04-6.55%Miss-12.8%131 up, 1 downAug 6, 2025$378.05M
    Mar 31, 2025$1.53$1.65$1.55 - $1.73-7.27%Miss-9.5%131 up, 1 downMay 7, 2025$372.76M
    Dec 31, 2024$1.59$1.54$1.44 - $1.72+3.04%Beat-9.1%130 up, 2 downFeb 26, 2025$391.11M
    Sep 30, 2024$1.70$1.56$1.45 - $1.74+8.97%Beat+15.6%110 up, 0 downNov 6, 2024$378.73M
    Jun 30, 2024$1.80$1.83$1.81 - $1.85-1.64%Miss+16.9%111 up, 0 downJul 31, 2024$394.09M
    Mar 31, 2024$1.69$1.54$1.52 - $1.62+9.74%Beat+15.0%100 up, 0 downMay 2, 2024$369.98M
    Dec 31, 2023$1.75$1.45$1.35 - $1.59+20.69%Beat+27.7%102 up, 0 downFeb 22, 2024$354.00M
    Sep 30, 2023$1.47$1.32$1.26 - $1.35+11.36%Beat+48.5%90 up, 0 downNov 2, 2023$319.95M
    Jun 30, 2023$1.54$1.31$1.28 - $1.37+17.56%Beat+73.0%80 up, 1 downAug 3, 2023$321.70M
    Mar 31, 2023$1.47$1.29$1.03 - $1.30+13.95%Beat+51.5%81 up, 0 downMay 4, 2023$300.78M
    Dec 31, 2022$1.37$0.96$0.89 - $1.01+42.71%Beat+448.0%72 up, 0 downFeb 23, 2023$263.17M
    Sep 30, 2022$0.99$0.83$0.75 - $0.86+19.28%Beat+1137.5%70 up, 0 downNov 3, 2022$239.29M
    Jun 30, 2022$0.89$0.70$0.70 - $0.71+27.14%Beat+709.1%30 up, 0 downAug 4, 2022$223.72M
    Mar 31, 2022$0.97$0.46$0.45 - $0.47+110.87%Beat+1840.0%40 up, 0 downApr 29, 2022$208.88M
    Dec 31, 2021$0.25$0.17$0.16 - $0.17+47.06%Beat+257.1%30 up, 0 downFeb 24, 2022$129.56M
    Sep 30, 2021$0.08$0.06$0.06 - $0.07+33.33%Beat+100.0%3N/ANov 4, 2021$102.07M
    Jun 30, 2021$0.11$0.05$0.04 - $0.06+120.00%Beat+10.0%4N/AJul 28, 2021$101.06M
    Mar 31, 2021$0.05-$0.01-$0.02 - $0.00+600.00%Beat-86.1%4N/AMay 4, 2021$92.51M
    Dec 31, 2020$0.07$0.01-$0.07 - $0.06+600.00%Beat-79.4%4N/AFeb 25, 2021$94.15M
    Sep 30, 2020$0.04-$0.06-$0.09 - $0.22+166.67%Beat-85.7%4N/ANov 5, 2020$88.54M
    Jun 30, 2020$0.10$0.06$0.02 - $0.15+66.67%Beat-63.0%4N/AJul 30, 2020$66.01M
    Mar 31, 2020$0.36$0.29N/A+24.14%Beat+28.6%3N/AApr 30, 2020$90.70M
    Dec 31, 2019$0.34$0.30$0.28 - $0.31+13.33%Beat+41.7%4N/AFeb 25, 2020$89.35M
    Sep 30, 2019$0.28$0.21$0.20 - $0.25+33.33%Beat+16.7%4N/AOct 31, 2019$85.78M
    Jun 30, 2019$0.27$0.25N/A+8.00%Beat+3.8%4N/AJul 25, 2019$85.70M
    Mar 31, 2019$0.28$0.25$0.24 - $0.25+12.00%Beat+27.3%4N/AApr 30, 2019$86.51M
    Dec 31, 2018$0.24$0.14$0.10 - $0.16+71.43%Beat+100.0%4N/AFeb 19, 2019$86.27M
    Sep 30, 2018$0.24$0.18$0.15 - $0.22+33.33%Beat0.0%4N/AOct 30, 2018$88.90M
    Jun 30, 2018$0.26$0.22$0.13 - $0.29+18.18%Beat-38.1%4N/AAug 1, 2018$85.57M
    Mar 31, 2018$0.22$0.22$0.20 - $0.240.00%In line-21.4%3N/AMay 2, 2018$82.63M
    Dec 31, 2017$0.12$0.20$0.11 - $0.28-40.00%Miss-33.3%4N/AFeb 26, 2018$81.24M
    Sep 30, 2017$0.24$0.20$0.19 - $0.23+20.00%Beat+60.0%4N/ANov 2, 2017$79.94M
    Jun 30, 2017$0.42$0.23$0.22 - $0.26+82.61%Beat+75.0%4N/AAug 1, 2017$88.84M
    Mar 31, 2017$0.28$0.19N/A+47.37%Beat+86.7%N/AN/AMay 2, 2017$81.36M
    Dec 31, 2016$0.18$0.13N/A+38.46%Beat+38.5%N/AN/AFeb 21, 2017$74.35M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $5.83, down 14.0% from the year before. It was $0.72 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$5.83-14.0%
    Dec 31, 2024$6.78+8.8%
    Dec 31, 2023$6.23+47.6%
    Dec 31, 2022$4.22+761.2%
    Dec 31, 2021$0.49-14.0%
    Dec 31, 2020$0.57-51.3%
    Dec 31, 2019$1.17+21.9%
    Dec 31, 2018$0.96-9.4%
    Dec 31, 2017$1.06+47.2%
    Dec 31, 2016$0.72N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 6,300 words across 13 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20266,29713
    2025Q4Dec 31, 20258,56515
    2025Q3Sep 30, 20254,78212
    2025Q2Jun 30, 20257,18117
    2025Q1Mar 31, 20258,34018
    2024Q4Dec 31, 20246,72118
    2024Q3Sep 30, 20247,06717
    2024Q2Jun 30, 20247,31618

    2026Q1 Earnings Call

    Opening remarks

    Mark Kinarney Vice President, Investor Relations Thank you. Good morning. With me today are Mary Heino, our CEO and Executive Chairperson; Amanda Morgan, our Chief Commercial Officer; and Bob Marshall, our CFO. We will begin with prepared remarks and then take your questions. This morning, we issued a press release, which was furnished to the SEC under Form 8-K reporting our first quarter 2026 results. The release and today's slide presentation are available on the Investors section of our website. Any comments could include forward-looking statements. Actual results may differ materially from these statements due to a variety of risks and uncertainties, which are detailed in our SEC filings. Discussions will also include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is included in the Investors section of our website. I will now turn the call over to Mary Heino.

    Mary Heino CEO and Executive Chairperson Thank you, Mark, and good morning, everyone. We had a strong start to the year with solid performance across PYLARIFY, NEUROCEQ and DEFINITY. These results reflect our ongoing commitment to focus and discipline across the organization. As we said last quarter, 2026 is a year of commercial execution and regulatory milestones. We're making deliberate choices about where we focus our commercial efforts and deploying capital so we're positioned to deliver solid results in 2026 and accelerate growth in 2027. Our corporate focus is centered on radiodiagnostics and our priorities for 2026 are clear. First, maintain our market leadership in PSMA PET while preparing for a seamless transition to PYLARIFY TRUVU, our newly approved PSMA PET formulation beginning in the fourth quarter. Second, continue to build momentum for NEUROCEQ through deeper penetration within existing accounts, leveraging the breadth of the Lantheus portfolio to unlock incremental growth opportunities and expanding our manufacturing footprint, increasing supply availability. Third, advance our late-stage clinical portfolio through key regulatory milestones and ensure launch readiness aligned with coding, coverage, payment, customer preparedness and market opportunity. And finally, allocate capital with discipline, prioritizing radiodiagnostics while evaluating value-maximizing alternatives for our radiotherapeutic assets. In addition to effective commercial execution, we advanced several key programs during the quarter that support our long-term growth strategy. On March 6, the FDA approved PYLARIFY TRUVU, our new PSMA PET imaging agent. PYLARIFY TRUVU offers the same proven diagnostic properties as PYLARIFY with a similar safety and efficacy profile. The value add of this product will be the larger batch sizes that can be enabled at manufacturing sites with high energy cyclotrons. This creates the potential to serve more patients and support a broader geographic reach.

    Frequently Asked Questions About LNTH

    When is Lantheus Holdings's next earnings date?

    Lantheus Holdings's next earnings report is expected for Feb 24, 2027.

    Did LNTH beat earnings estimates last quarter?

    Yes. Lantheus Holdings reported EPS of $1.43 for the quarter ended Sep 30, 2026, above the $1.01 estimate, a 41.58% surprise.

    What EPS do analysts expect from LNTH next quarter?

    The consensus EPS estimate for Lantheus Holdings for the quarter ending Dec 31, 2026 is $1.36 from 11 analysts, with estimates from $1.02 to $1.63.

    How often does LNTH beat earnings estimates?

    Lantheus Holdings beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +15.47%.